SpyGlass Pharma, Inc.
The Seagull Executive Verdict
SpyGlass Pharma, Inc. sells products and services in the Health Care market. The company went public in 2026 to raise cash from public stock markets.
Bankers told everyday buyers that SpyGlass Pharma, Inc. would grow fast and dominate its market.
The stock climbed 63.94% after the IPO, holding value better than many other 2026 listings.
Capital Formation & Float Scarcity
Standard primary capital raise for general working capital.
Insider Lock-Up Expiration
Standard 180-day lockup period restricts insider trading until approximately 2026-08-05.
Underwriter Syndicate & Fee Extraction
Sector Peer & Cohort Telemetry
SpyGlass Pharma, Inc. is currently trading above the Health Care sector median of 21.64%. Across the entire 2026 calendar year cohort, only 78% of Health Care offerings have sustained a positive return above their initial offer price.